Blood–Brain Barrier: Structure, Function, Diseases, and Drug Delivery Systems

Abstract

The blood–brain barrier (BBB) is a highly selective and dynamic neurovascular interface essential for maintaining central nervous system homeostasis. This specialized barrier comprises brain microvascular endothelial cells interconnected by tight junctions, supported by pericytes and astrocytic end-feet within the neurovascular unit. While protecting the brain from circulating pathogens and toxins, the BBB presents formidable obstacles to drug delivery, restricting approximately 98% of small-molecule therapeutics and nearly all large biomolecules from reaching the brain parenchyma. BBB dysfunction is critically implicated in the pathogenesis and progression of numerous neurological disorders, including ischemic stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and brain tumors. This comprehensive review systematically examines the structural organization and functional characteristics of the BBB, elucidates its pathophysiological roles across major neurological diseases, and critically evaluates innovative drug delivery strategies designed to overcome this biological barrier. We analyze passive targeting approaches, active targeting mechanisms via receptor-mediated transcytosis, and stimuli-responsive systems including focused ultrasound and magnetic guidance. Additionally, we discuss multifunctional nanoplatforms, biomimetic cell membrane-coated delivery systems, current preclinical evidence, and clinical translation challenges. Finally, we propose future research directions and identify specific experimental pathways to accelerate the development of next-generation BBB-targeted therapeutics from preclinical promise to clinical application.

Keywords

blood–brain barrier / drug delivery systems / ischemic stroke / nanoparticles / neurological diseases / neurovascular unit / targeted therapy

References

[1] C. P. Profaci, R. N. Munji, R. S. Pulido, and R. Daneman, “The Blood-Brain Barrier in Health and Disease: Important Unanswered Questions,” The Journal of Experimental Medicine 217, no. 4 (2020): e20190062.

[2] M. D. Sweeney, Z. Zhao, A. Montagne, A. R. Nelson, and B. V. Zlokovic, “Blood-Brain Barrier: from Physiology to Disease and Back,” Physiological Reviews 99, no. 1 (2019): 21–78.

[3] H. Kadry, B. Noorani, and L. Cucullo, “A Blood-Brain Barrier Overview on Structure, Function, Impairment, and Biomarkers of Integrity,” Fluids and Barriers of the CNS 17, no. 1 (2020): 69.

[4] N. J. Abbott, L. Rönnbäck, and E. Hansson, “Astrocyte-Endothelial Interactions at the Blood-Brain Barrier,” Nature Reviews Neuroscience 7, no. 1 (2006): 41–53.

[5] H. Fong, B. Zhou, H. Feng, et al., “Recapitulation of Structure-Function-Regulation of Blood-Brain Barrier under (Patho)Physiological Conditions,” Cells 13, no. 3 (2024): 260.

[6] D. Wu, Q. Chen, X. Chen, F. Han, Z. Chen, and Y. Wang, “The Blood-Brain Barrier: Structure, Regulation, and Drug Delivery,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 217.

[7] A. Friedman, O. Prager, Y. Serlin, and D. Kaufer, “Dynamic Modulation of the Blood-Brain Barrier in the Healthy Brain,” Nature Reviews Neuroscience 26, no. 12 (2025): 749–764.

[8] C. Iadecola, “The Neurovascular Unit Coming of Age: a Journey through Neurovascular Coupling in Health and Disease,” Neuron 96, no. 1 (2017): 17–42.

[9] W. A. Banks, “From Blood-Brain Barrier to Blood-Brain Interface: New Opportunities for CNS Drug Delivery,” Nature Reviews Drug Discovery 15, no. 4 (2016): 275–292.

[10] M. Segarra, M. R. Aburto, and A. Acker-Palmer, “Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis,” Trends in Neurosciences 44, no. 5 (2021): 393–405.

[11] T. Chen, Y. Dai, C. Hu, et al., “Cellular and Molecular Mechanisms of the Blood-Brain Barrier Dysfunction in Neurodegenerative Diseases,” Fluids and Barriers of the CNS 21, no. 1 (2024): 60.

[12] P. T. Ronaldson and T. P. Davis, “Blood-Brain Barrier Transporters: a Translational Consideration for CNS Delivery of Neurotherapeutics,” Expert Opinion on Drug Delivery 21, no. 1 (2024): 71–89.

[13] E. G. Knox, M. R. Aburto, G. Clarke, J. F. Cryan, and C. M. O'Driscoll, “The Blood-Brain Barrier in Aging and Neurodegeneration,” Molecular Psychiatry 27, no. 6 (2022): 2659–2673.

[14] B. Zierfuss, C. Larochelle, and A. Prat, “Blood-Brain Barrier Dysfunction in Multiple Sclerosis: Causes, Consequences, and Potential Effects of Therapies,” The Lancet Neurology 23, no. 1 (2024): 95–109.

[15] S. R. French, B. P. Meyer, J. C. Arias, S. R. Levendovzsky, and C. C. Weinkauf, “Biomarkers of Blood-Brain Barrier and Neurovascular Unit Integrity in human Cognitive Impairment and Dementia,” Alzheimer's & Dementia 21, no. 3 (2025): e70104.

[16] K. L. Nilles, E. I. Williams, R. D. Betterton, T. P. Davis, and P. T. Ronaldson, “Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke,” International Journal of Molecular Sciences 23, no. 3 (2022): 1898.

[17] S. Zha, H. Liu, H. Li, H. Li, K. Wong, and A. H. All, “Functionalized Nanomaterials Capable of Crossing the Blood-Brain Barrier,” ACS Nano 18, no. 3 (2024): 1820–1845.

[18] S. Jo, I. Sun, C. Ahn, S. Lee, and K. Kim, “Recent Trend of Ultrasound-Mediated Nanoparticle Delivery for Brain Imaging and Treatment,” ACS Applied Materials & Interfaces 15, no. 1 (2023): 120–137.

[19] S. Liu, X. Jin, Y. Ge, et al., “Advances in Brain-targeted Delivery Strategies and Natural Product-mediated Enhancement of Blood-Brain Barrier Permeability,” Journal of Nanobiotechnology 23, no. 1 (2025): 382.

[20] Z. Qu, J. Luo, Z. Li, et al., “Advancements in Strategies for Overcoming the Blood-Brain Barrier to Deliver Brain-targeted Drugs,” Frontiers in Aging Neuroscience 16 (2024): 1353003.

[21] J. J. Lochhead, J. Yang, P. T. Ronaldson, and T. P. Davis, “Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders,” Frontiers in Physiology 11 (2020): 914.

[22] P. T. Ronaldson and T. P. Davis, “Regulation of Blood-Brain Barrier Integrity by Microglia in Health and Disease: a Therapeutic Opportunity,” Journal of Cerebral Blood Flow and Metabolism 40, no. 1_suppl (2020): S6–S24.

[23] A. Ben-Zvi and S. Liebner, “Developmental Regulation of Barrier- and Non-barrier Blood Vessels in the CNS,” Journal of Internal Medicine 292, no. 1 (2022): 31–46.

[24] N. Kutuzov, H. Flyvbjerg, and M. Lauritzen, “Contributions of the Glycocalyx, Endothelium, and Extravascular Compartment to the Blood-Brain Barrier,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 40 (2018): E9429–E9438.

[25] K. Veys, Z. Fan, M. Ghobrial, et al., “Role of the GLUT1 Glucose Transporter in Postnatal CNS Angiogenesis and Blood-Brain Barrier Integrity,” Circulation Research 127, no. 4 (2020): 466–482.

[26] M. Taslimifar, M. Faltys, V. Kurtcuoglu, F. Verrey, and V. Makrides, “Analysis of L-leucine Amino Acid Transporter Species Activity and Gene Expression by human Blood Brain Barrier hCMEC/D3 Model Reveal Potential LAT1, LAT4, B0AT2 and y+LAT1 Functional Cooperation,” Journal of Cerebral Blood Flow and Metabolism 42, no. 1 (2022): 90–103.

[27] W. M. Pardridge, “Receptor-mediated Drug Delivery of Bispecific Therapeutic Antibodies through the Blood-Brain Barrier,” Frontiers in Drug Delivery 3 (2023): 1227816.

[28] Y. Hashimoto and M. Campbell, “Tight Junction Modulation at the Blood-Brain Barrier: Current and Future Perspectives,” Biochimica et Biophysica Acta Biomembranes 1862, no. 9 (2020): 183298.

[29] Y. Hashimoto, C. Greene, A. Munnich, and M. Campbell, “The CLDN5 Gene at the Blood-Brain Barrier in Health and Disease,” Fluids and Barriers of the CNS 20, no. 1 (2023): 22.

[30] D. Kempuraj, K. D. Dourvetakis, J. Cohen, et al., “Neurovascular Unit, Neuroinflammation and Neurodegeneration Markers in Brain Disorders,” Frontiers in Cellular Neuroscience 18 (2024): 1491952.

[31] E. Wakayama, T. Kuzu, K. Tachibana, R. Hirayama, Y. Okada, and M. Kondoh, “Modifying the Blood-Brain Barrier by Targeting Claudin-5: Safety and Risks,” Annals of the New York Academy of Sciences 1514, no. 1 (2022): 62–69.

[32] D. Kempuraj, K. K. Aenlle, J. Cohen, et al., “COVID-19 and Long COVID: Disruption of the Neurovascular Unit, Blood-Brain Barrier, and Tight Junctions,” The Neuroscientist 30, no. 4 (2024): 421–439.

[33] S. Ornelas, A. Berthiaume, S. K. Bonney, et al., “Three-dimensional Ultrastructure of the Brain Pericyte-Endothelial Interface,” Journal of Cerebral Blood Flow and Metabolism 41, no. 9 (2021): 2185–2200.

[34] C. A. Dessalles, A. Babataheri, and A. I. Barakat, “Pericyte Mechanics and Mechanobiology,” Journal of Cell Science 134, no. 6 (2021): jcs240226.

[35] T. Y. You, Q. Dong, and M. Cui, “Emerging Links between Cerebral Blood Flow Regulation and Cognitive Decline: a Role for Brain Microvascular Pericytes,” Aging and Disease 14, no. 4 (2023): 1276–1291.

[36] D. A. Hartmann, V. Coelho-Santos, and A. Y. Shih, “Pericyte Control of Blood Flow across Microvascular Zones in the Central Nervous System,” Annual Review of Physiology 84 (2022): 331–354.

[37] M. A. Mäe, L. He, S. Nordling et al., “Single-Cell Analysis of Blood-Brain Barrier Response to Pericyte Loss,” Circulation Research 128, no. 4 (2021): e46–e62.

[38] F. Bohler, L. Bohler, and V. Taranikanti, “Targeting Pericyte Retention in Diabetic Retinopathy: a Review,” Annals of Medicine 56, no. 1 (2024): 2398200.

[39] Y. Zhang, B. Mu, Z. Ran, et al., “Pericytes in Alzheimer's Disease: Key Players and Therapeutic Targets,” Experimental Neurology 379 (2024): 114825.

[40] B. Díaz-Castro, S. Robel, and A. Mishra, “Astrocyte Endfeet in Brain Function and Pathology: Open Questions,” Annual Review of Neuroscience 46 (2023): 101–121.

[41] W. A. Mills, A. M. Woo, S. Jiang, et al., “Astrocyte Plasticity in Mice Ensures Continued Endfoot Coverage of Cerebral Blood Vessels Following Injury and Declines with Age,” Nature Communications 13, no. 1 (2022): 1794.

[42] M. M. Salman, P. Kitchen, A. Halsey, et al., “Emerging Roles for Dynamic Aquaporin-4 Subcellular Relocalization in CNS Water Homeostasis,” Brain 145, no. 1 (2022): 64–75.

[43] I. Silva, J. Silva, R. Ferreira, and D. Trigo, “Glymphatic System, AQP4, and Their Implications in Alzheimer's Disease,” Neurological Research and Practice 3, no. 1 (2021): 5.

[44] S. Michinaga and Y. Koyama, “Dual Roles of Astrocyte-Derived Factors in Regulation of Blood-Brain Barrier Function after Brain Damage,” International Journal of Molecular Sciences 20, no. 3 (2019): 571.

[45] A. Institoris, M. Vandal, G. Peringod, et al., “Astrocytes Amplify Neurovascular Coupling to Sustained Activation of Neocortex in Awake Mice,” Nature Communications 13, no. 1 (2022): 7872.

[46] M. D. Sweeney, A. P. Sagare, and B. V. Zlokovic, “Blood-Brain Barrier Breakdown in Alzheimer Disease and Other Neurodegenerative Disorders,” Nature Reviews Neurology 14, no. 3 (2018): 133–150.

[47] W. C. Meijer and J. A. Gorter, “Role of Blood-Brain Barrier Dysfunction in the Development of Poststroke Epilepsy,” Epilepsia 65, no. 9 (2024): 2519–2536.

[48] L. Xu, A. Nirwane, and Y. Yao, “Basement Membrane and Blood-Brain Barrier,” Stroke and Vascular Neurology 4, no. 2 (2019): 78–82.

[49] M. J. Reed, M. Damodarasamy, and W. A. Banks, “The Extracellular Matrix of the Blood-Brain Barrier: Structural and Functional Roles in Health, Aging, and Alzheimer's Disease,” Tissue Barriers 7, no. 4 (2019): 1651157.

[50] M. Jeanne, J. Jorgensen, and D. B. Gould, “Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention,” Circulation 131, no. 18 (2015): 1555–1565.

[51] M. S. Thomsen, L. J. Routhe, and T. Moos, “The Vascular Basement Membrane in the Healthy and Pathological Brain,” Journal of Cerebral Blood Flow and Metabolism 37, no. 10 (2017): 3300–3317.

[52] J. Song, X. Zhang, K. Buscher, et al., “Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration,” Cell Reports 18, no. 5 (2017): 1256–1269.

[53] R. J. Turner and F. R. Sharp, “Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke,” Frontiers in Cellular Neuroscience 10 (2016): 56.

[54] R. G. Rempe, A. M. Hartz, and B. Bauer, “Matrix Metalloproteinases in the Brain and Blood-Brain Barrier: Versatile Breakers and Makers,” Journal of Cerebral Blood Flow and Metabolism 36, no. 9 (2016): 1481–1507.

[55] C. Greene, N. Hanley, and M. Campbell, “Claudin-5: Gatekeeper of Neurological Function,” Fluids and Barriers of the CNS 16, no. 1 (2019): 3.

[56] N. Hudson and M. Campbell, “Tight Junctions of the Neurovascular Unit,” Frontiers in Molecular Neuroscience 14 (2021): 752781.

[57] A. A. Scalise, N. Kakogiannos, F. Zanardi, F. Iannelli, and M. Giannotta, “The Blood-Brain and Gut-vascular Barriers: from the Perspective of Claudins,” Tissue Barriers 9, no. 3 (2021): 1926190.

[58] L. Kaplan, B. W. Chow, and C. Gu, “Neuronal Regulation of the Blood-Brain Barrier and Neurovascular Coupling,” Nature Reviews Neuroscience 21, no. 8 (2020): 416–432.

[59] C. Tincu (Iurciuc), C. V. Andrițoiu, M. Popa, and L. Ochiuz, “Recent Advancements and Strategies for Overcoming the Blood-Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma,” Polymers 15, no. 19 (2023): 3969.

[60] S. P. Rendić, R. D. Crouch, F. P. Guengerich, et al., “Roles of Selected Non-P450 human Oxidoreductase Enzymes in Protective and Toxic Effects of Chemicals: Review and Compilation of Reactions,” Archives of Toxicology 96, no. 8 (2022): 2145–2246.

[61] J. A. Schulz, A. M. Hartz, and B. Bauer, “ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery,” Pharmacological Reviews 75, no. 5 (2023): 815–853.

[62] N. Tournier and O. Langer, “Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria,” Journal of Nuclear Medicine 66, no. 5 (2025): 676–680.

[63] R. Liu, J. M. Collier, N. H. Abdul-Rahman, O. Capuk, Z. Zhang, and G. Begum, “Dysregulation of Ion Channels and Transporters and Blood-Brain Barrier Dysfunction in Alzheimer's Disease and Vascular Dementia,” Aging and Disease 15, no. 4 (2024): 1748–1770.

[64] M. Xiao, Z. J. Xiao, B. Yang, Z. Lan, and F. Fang, “Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis than Victim in Neurological Disorders,” Frontiers in Neuroscience 14 (2020): 764.

[65] S. B. Hladky and M. A. Barrand, “Fluid and Ion Transfer across the Blood-Brain and Blood-cerebrospinal Fluid Barriers; a Comparative Account of Mechanisms and Roles,” Fluids and Barriers of the CNS 13, no. 1 (2016): 19.

[66] K. Lykke, M. Assentoft, S. Hørlyck, et al., “Evaluating the Involvement of Cerebral Microvascular Endothelial Na+/K+-ATPase and Na+-K+-2Cl- co-transporter in Electrolyte Fluxes in an in Vitro Blood-Brain Barrier Model of Dehydration,” Journal of Cerebral Blood Flow and Metabolism 39, no. 3 (2019): 497–512.

[67] R. A. Hawkins and J. R. Viña, “How Glutamate Is Managed by the Blood-Brain Barrier,” Biology 5, no. 4 (2016): 37.

[68] D. Zhang, Z. Hua, and Z. Li, “The Role of Glutamate and Glutamine Metabolism and Related Transporters in Nerve Cells,” CNS Neuroscience & Therapeutics 30, no. 2 (2024): e14617.

[69] M. Castro and M. Potente, “The Blood-Brain Barrier-a Metabolic Ecosystem,” The EMBO Journal 41, no. 9 (2022): e111189.

[70] M. D. Sweeney, K. Kisler, A. Montagne, A. W. Toga, and B. V. Zlokovic, “The Role of Brain Vasculature in Neurodegenerative Disorders,” Nature Neuroscience 21, no. 10 (2018): 1318–1331.

[71] Y. Zhu, A. Verkhratsky, H. Chen, and C. Yi, “Understanding Glucose Metabolism and Insulin Action at the Blood-Brain Barrier: Implications for Brain Health and Neurodegenerative Diseases,” Acta Physiologica 241, no. 2 (2025): e14283.

[72] H. S. Ahmed, “The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential,” Molecular Neurobiology 62, no. 3 (2025): 3813–3832.

[73] W. M. Pardridge, “Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain,” Frontiers in Aging Neuroscience 11 (2019): 373.

[74] M. A. Felmlee, R. S. Jones, V. Rodriguez-Cruz, K. E. Follman, and M. E. Morris, “Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease,” Pharmacological Reviews 72, no. 2 (2020): 466–485.

[75] M. Ramezani, M. Fernando, S. Eslick, et al., “Ketone Bodies Mediate Alterations in Brain Energy Metabolism and Biomarkers of Alzheimer's Disease,” Frontiers in Neuroscience 17 (2023): 1297984.

[76] J. I. Morrison, A. Petrovic, N. G. Metzendorf, et al., “Standardized Preclinical in Vitro Blood-Brain Barrier Mouse Assay Validates Endocytosis-Dependent Antibody Transcytosis Using Transferrin-Receptor-Mediated Pathways,” Molecular Pharmaceutics 20, no. 3 (2023): 1564–1576.

[77] F. Shimizu and M. Nakamori, “Blood-Brain Barrier Disruption in Neuroimmunological Disease,” International Journal of Molecular Sciences 25, no. 19 (2024): 10625.

[78] B. Engelhardt, P. Vajkoczy, and R. O. Weller, “The Movers and Shapers in Immune Privilege of the CNS,” Nature Immunology 18, no. 2 (2017): 123–131.

[79] C. Acioglu and S. Elkabes, “Innate Immune Sensors and Regulators at the Blood Brain Barrier: Focus on Toll-like Receptors and Inflammasomes as Mediators of Neuro-immune Crosstalk and Inflammation,” Journal of Neuroinflammation 22, no. 1 (2025): 39.

[80] V. Kumar, “Toll-like Receptors in the Pathogenesis of Neuroinflammation,” Journal of Neuroimmunology 332 (2019): 16–30.

[81] A. V. Andjelkovic, M. Situ, A. F. Citalan-Madrid, S. M. Stamatovic, J. Xiang, and R. F. Keep, “Blood-Brain Barrier Dysfunction in Normal Aging and Neurodegeneration: Mechanisms, Impact, and Treatments,” Stroke 54, no. 3 (2023): 661–672.

[82] S. Kim, U. J. Jung, and S. R. Kim, “Role of Oxidative Stress in Blood-Brain Barrier Disruption and Neurodegenerative Diseases,” Antioxidants 13, no. 12 (2024): 1462.

[83] GBD 2021 Stroke Risk Factor Collaborators, “Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990–2021: a Systematic Analysis for the Global Burden of Disease Study 2021,” The Lancet Neurology 23, no. 10 (2024): 973–1003.

[84] J. Fan, X. Li, X. Yu, et al., “Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990–2030,” Neurology 101, no. 2 (2023): e137–e150.

[85] S. Bernardo-Castro, J. A. Sousa, E. Martins, et al., “The Evolution of Blood-Brain Barrier Permeability Changes after Stroke and Its Implications on Clinical Outcome: a Systematic Review and Meta-analysis,” International Journal of Stroke 18, no. 7 (2023): 783–794.

[86] Y. Liang, Y. Yu, J. Liu, et al., “Blood-Brain Barrier Disruption and Hemorrhagic Transformation in Acute Stroke before Endovascular Reperfusion Therapy,” Frontiers in Neurology 15 (2024): 1349369.

[87] S. H. Yang and R. Liu, “Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke,” Translational Stroke Research 12, no. 6 (2021): 937–945.

[88] E. Candelario-Jalil, R. M. Dijkhuizen, and T. Magnus, “Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities,” Stroke 53, no. 5 (2022): 1473–1486.

[89] C. Yang, K. E. Hawkins, S. Doré, and E. Candelario-Jalil, “Neuroinflammatory Mechanisms of Blood-Brain Barrier Damage in Ischemic Stroke,” American Journal of Physiology Cell Physiology 316, no. 2 (2019): C135–C153.

[90] X. Zheng, B. Ren, and Y. Gao, “Tight Junction Proteins Related to Blood-Brain Barrier and Their Regulatory Signaling Pathways in Ischemic Stroke,” Biomedicine & Pharmacotherapy 165 (2023): 115272.

[91] S. Sugiyama, T. Sasaki, H. Tanaka, et al., “The Tight Junction Protein Occludin Modulates Blood-Brain Barrier Integrity and Neurological Function after Ischemic Stroke in Mice,” Scientific Reports 13, no. 1 (2023): 2892.

[92] Y. Ji, Q. Gao, Y. Ma, et al., “An MMP-9 Exclusive Neutralizing Antibody Attenuates Blood-Brain Barrier Breakdown in Mice with Stroke and Reduces Stroke Patient-derived MMP-9 Activity,” Pharmacological Research 190 (2023): 106720.

[93] Y. Yao, F. Liu, Z. Gu, et al., “Emerging Diagnostic Markers and Therapeutic Targets in Post-stroke Hemorrhagic Transformation and Brain Edema,” Frontiers in Molecular Neuroscience 16 (2023): 1286351.

[94] X. Jiang, A. V. Andjelkovic, L. Zhu, et al., “Blood-Brain Barrier Dysfunction and Recovery after Ischemic Stroke,” Progress in Neurobiology 163–164 (2018): 144–171.

[95] K. Mathias, R. S. Machado, S. Stork, et al., “Blood-Brain Barrier Permeability in the Ischemic Stroke: an Update,” Microvascular Research 151 (2024): 104621.

[96] R. L. Jayaraj, S. Azimullah, R. Beiram, F. Y. Jalal, and G. A. Rosenberg, “Neuroinflammation: Friend and Foe for Ischemic Stroke,” Journal of Neuroinflammation 16, no. 1 (2019): 142.

[97] Z. Xu, F. Yang, and L. Zheng, “Uncovering the Dual Roles of Peripheral Immune Cells and Their Connections to Brain Cells in Stroke and Post-stroke Stages through Single-cell Sequencing,” Frontiers in Neuroscience 18 (2024): 1443438.

[98] Y. Liang, Y. Jiang, J. Liu, et al., “Blood-Brain Barrier Disruption and Imaging Assessment in Stroke,” Translational Stroke Research 16, no. 4 (2025): 1400–1411.

[99] D. S. Knopman, H. Amieva, R. C. Petersen, et al., “Alzheimer Disease,” Nature Reviews Disease Primers 7, no. 1 (2021): 33.

[100] P. Scheltens, B. De Strooper, M. Kivipelto, et al., “Alzheimer's Disease,” Lancet 397, no. 10284 (2021): 1577–1590.

[101] D. A. Nation, M. D. Sweeney, A. Montagne, et al., “Blood-Brain Barrier Breakdown Is an Early Biomarker of human Cognitive Dysfunction,” Nature Medicine 25, no. 2 (2019): 270–276.

[102] G. Barisano, A. Montagne, K. Kisler, J. A. Schneider, J. M. Wardlaw, and B. V. Zlokovic, “Blood-Brain Barrier Link to human Cognitive Impairment and Alzheimer's Disease,” Nature Cardiovascular Research 1, no. 2 (2022): 108–115.

[103] A. Montagne, S. Barnes, M. Sweeney, et al., “Blood-Brain Barrier Breakdown in the Aging human Hippocampus,” Neuron 85, no. 2 (2015): 296–302.

[104] M. Denkinger, S. Baker, B. Inglis, et al., “Associations between Regional Blood-Brain Barrier Permeability, Aging, and Alzheimer's Disease Biomarkers in Cognitively Normal Older Adults,” PLoS One 19, no. 6 (2024): e0299764.

[105] A. E. Alkhalifa, N. F. Al-Ghraiybah, J. Odum, J. G. Shunnarah, N. Austin, and A. Kaddoumi, “Blood-Brain Barrier Breakdown in Alzheimer's Disease: Mechanisms and Targeted Strategies,” International Journal of Molecular Sciences 24, no. 22 (2023): 16288.

[106] N. Korte, A. Barkaway, J. Wells, et al., “Inhibiting Ca2+ Channels in Alzheimer's Disease Model Mice Relaxes Pericytes, Improves Cerebral Blood Flow and Reduces Immune Cell Stalling and Hypoxia,” Nature Neuroscience 27, no. 11 (2024): 2086–2100.

[107] A. Berthiaume, F. Schmid, S. Stamenkovic, et al., “Pericyte Remodeling Is Deficient in the Aged Brain and Contributes to Impaired Capillary Flow and Structure,” Nature Communications 13, no. 1 (2022): 5912.

[108] S. Petralla, M. Panayotova, E. Franchina, G. Fricker, and E. Puris, “Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer's Disease,” Pharmaceutics 16, no. 7 (2024): 948.

[109] J. Lee, H. Lee, H. Lee, et al., “ANKS1A regulates LDL Receptor-related Protein 1 (LRP1)-mediated Cerebrovascular Clearance in Brain Endothelial Cells,” Nature Communications 14, no. 1 (2023): 8463.

[110] R. A. Fisher, J. S. Miners, and S. Love, “Pathological Changes within the Cerebral Vasculature in Alzheimer's Disease: New Perspectives,” Brain Pathology 32, no. 6 (2022): e13061.

[111] M. Merlini, V. A. Rafalski, P. E. Rios Coronado, et al., “Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model,” Neuron 101, no. 6 (2019): 1099–1108.e6.

[112] S. Kim, C. Sharma, U. J. Jung, and S. R. Kim, “Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer's Disease,” Biomedicines 11, no. 5 (2023): 1383.

[113] S. R. L. Vieira and A. H. V. Schapira, “Glucocerebrosidase Mutations and Parkinson Disease,” Journal of Neural Transmission 129, no. 9 (2022): 1105–1117.

[114] K. Lau, R. Kotzur, and F. Richter, “Blood-Brain Barrier Alterations and Their Impact on Parkinson's Disease Pathogenesis and Therapy,” Translational Neurodegeneration 13, no. 1 (2024): 37.

[115] D. Dik, G. M. Halliday, V. Sytnyk, and C. E. Shepherd, “Region-specific Variations in the Cerebrovasculature Underlie Disease Progression in Parkinson's Disease,” Brain 149, no. 2 (2026): 592–605.

[116] K. Lau, L. T. Porschen, F. Richter, and B. Gericke, “Microvascular Blood-Brain Barrier Alterations in Isolated Brain Capillaries of Mice Over-expressing Alpha-synuclein (Thy1-aSyn line 61),” Neurobiology of Disease 187 (2023): 106298.

[117] T. Wang, M. Li, Z. Pei, Q. Chen, Q. Cheng, and Z. Li, “Down-regulation of Platelet-derived Growth Factor Receptor β in Pericytes Increases Blood-Brain Barrier Permeability and Significantly Enhances α-synuclein in a Parkinson's Disease 3D Cell Model in Vitro under Hyperglycemic Condition,” Tissue & Cell 93 (2025): 102751.

[118] R. Gabdulkhaev, H. Shimizu, M. Kanazawa, et al., “Blood-Brain Barrier Dysfunction in Multiple System Atrophy: a human Postmortem Study,” Neuropathology 45, no. 3 (2025): 210–222.

[119] J. Huang, J. Ding, X. Wang, et al., “Transfer of Neuron-derived α-synuclein to Astrocytes Induces Neuroinflammation and Blood-Brain Barrier Damage after Methamphetamine Exposure: Involving the Regulation of Nuclear Receptor-associated Protein 1,” Brain, Behavior, and Immunity 106 (2022): 247–261.

[120] J. Gan, Z. Xu, Z. Chen, et al., “Blood-Brain Barrier Breakdown in Dementia with Lewy Bodies,” Fluids and Barriers of the CNS 21, no. 1 (2024): 73.

[121] Y. Meng, C. B. Pople, Y. Huang, et al., “Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: a Phase I Study,” Movement Disorders 37, no. 10 (2022): 2134–2139.

[122] T. Liu and J. Wei, “FGF21 confers Neuroprotection in Parkinson's Disease by Activating the FGFR1-sirt1 Pathway,” Cellular & Molecular Biology Letters 30, no. 1 (2025): 127.

[123] Y. Zhou, Y. Xu, X. Ren, and X. Zhang, “Inactivation of Microglia Dampens Blood-Brain Barrier Permeability and Loss of Dopaminergic Neurons in Paraquat-lesioned Mice,” Food and Chemical Toxicology 174 (2023): 113692.

[124] G. Lan, P. Wang, R. B. Chan, et al., “Astrocytic VEGFA: an Essential Mediator in Blood-Brain-barrier Disruption in Parkinson's Disease,” Glia 70, no. 2 (2022): 337–353.

[125] M. F. Munoz-Pinto, E. Candeias, I. Melo-Marques, et al., “Gut-first Parkinson's Disease Is Encoded by Gut Dysbiome,” Molecular Neurodegeneration 19, no. 1 (2024): 78.

[126] A. M. Schonhoff, D. A. Figge, G. P. Williams, et al., “Border-associated Macrophages Mediate the Neuroinflammatory Response in an Alpha-synuclein Model of Parkinson disease,” Nature Communications 14, no. 1 (2023): 3754.

[127] S. Bido, M. Nannoni, S. Muggeo, et al., “Microglia-specific IL-10 Gene Delivery Inhibits Neuroinflammation and Neurodegeneration in a Mouse Model of Parkinson's Disease,” Science Translational Medicine 16, no. 761 (2024): eadm8563.

[128] X. Sun, R. Gu, and J. Bai, “Differentiation and Regulation of CD4+ T Cell Subsets in Parkinson's Disease,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 352.

[129] K. Hutchinson, D. B. Silva, J. Bohlke, et al., “Describing Inhibitor Specificity for the Amino Acid Transporter LAT1 from Metainference Simulations,” Biophysical Journal 121, no. 23 (2022): 4476–4491.

[130] E. Kamma, W. Lasisi, C. Libner, H. S. Ng, and J. R. Plemel, “Central Nervous System Macrophages in Progressive Multiple Sclerosis: Relationship to Neurodegeneration and Therapeutics,” Journal of Neuroinflammation 19, no. 1 (2022): 45.

[131] S. Rida Zainab, J. Zeb Khan, M. Khalid Tipu, F. Jahan, and N. Irshad, “A Review on Multiple Sclerosis: Unravelling the Complexities of Pathogenesis, Progression, Mechanisms and Therapeutic Innovations,” Neuroscience 567 (2025): 133–149.

[132] D. Schafflick, C. A. Xu, M. Hartlehnert, et al., “Integrated Single Cell Analysis of Blood and Cerebrospinal Fluid Leukocytes in Multiple Sclerosis,” Nature Communications 11, no. 1 (2020): 247.

[133] A. Kendirli, C. de la Rosa, K. F. Lämmle, et al., “A Genome-wide in Vivo CRISPR Screen Identifies Essential Regulators of T Cell Migration to the CNS in a Multiple Sclerosis Model,” Nature Neuroscience 26, no. 10 (2023): 1713–1725.

[134] À. Rovira, F. M. Doniselli, C. Auger, et al., “Use of Gadolinium-based Contrast Agents in Multiple Sclerosis: a Review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group,” European Radiology 34, no. 3 (2024): 1726–1735.

[135] A. M. Thomas, F. Barkhof, and J. W. M. Bulte, “Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment,” Radiology 303, no. 3 (2022): 486–497.

[136] R. Balasa, L. Barcutean, A. Balasa, A. Motataianu, C. Roman-Filip, and D. Manu, “The Action of TH17 Cells on Blood Brain Barrier in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis,” Human Immunology 81, no. 5 (2020): 237–243.

[137] M. Zeitelhofer, M. Z. Adzemovic, C. Moessinger, et al., “Blocking PDGF-CC Signaling Ameliorates Multiple Sclerosis-like Neuroinflammation by Inhibiting Disruption of the Blood-Brain Barrier,” Scientific Reports 10, no. 1 (2020): 22383.

[138] Z. Khan, S. Mehan, G. D. Gupta, and A. S. Narula, “Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications,” Neuroscience 548 (2024): 9–26.

[139] S. F. Spampinato, S. Merlo, Y. Sano, T. Kanda, and M. A. Sortino, “Protective Effect of the Sphingosine-1 Phosphate Receptor Agonist siponimod on Disrupted Blood Brain Barrier Function,” Biochemical Pharmacology 186 (2021): 114465.

[140] D. Leppert, M. Watanabe, S. Schaedelin, et al., “Granulocyte Activation Markers in Cerebrospinal Fluid Differentiate Acute Neuromyelitis Spectrum Disorder from Multiple Sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry 94, no. 9 (2023): 726–737.

[141] P. Kuo, W. Weng, B. A. Scofield, et al., “Interferon-β Alleviates Delayed tPA-induced Adverse Effects via Modulation of MMP3/9 Production in Ischemic Stroke,” Blood Advances 4, no. 18 (2020): 4366–4381.

[142] Y. Takai, T. Misu, K. Kaneko, et al., “Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: an Immunopathological Study,” Brain 143, no. 5 (2020): 1431–1446.

[143] S. Gupta, M. Simic, S. A. Sagan, et al., “CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity,” Neurology Neuroimmunology & Neuroinflammation 10, no. 2 (2023): e200080.

[144] R. Höftberger, H. Lassmann, T. Berger, and M. Reindl, “Pathogenic Autoantibodies in Multiple Sclerosis - from a Simple Idea to a Complex Concept,” Nature Reviews Neurology 18, no. 11 (2022): 681–688.

[145] S. K. Halder and R. Milner, “Hypoxia in Multiple Sclerosis; Is It the Chicken or the Egg?” Brain 144, no. 2 (2021): 402–410.

[146] I. J. Tagge, V. C. Anderson, C. S. Springer, et al., “Gray Matter Blood-Brain Barrier Water Exchange Dynamics Are Reduced in Progressive Multiple Sclerosis,” Journal of Neuroimaging 31, no. 6 (2021): 1111–1118.

[147] P. S. Steeg, “The Blood-tumour Barrier in Cancer Biology and Therapy,” Nature Reviews Clinical Oncology 18, no. 11 (2021): 696–714.

[148] C. Hempel, K. B. Johnsen, S. Kostrikov, P. Hamerlik, and T. L. Andresen, “Brain Tumor Vessels-a Barrier for Drug Delivery,” Cancer Metastasis Reviews 39, no. 3 (2020): 959–968.

[149] D. H. Upton, C. Ung, S. M. George, M. Tsoli, M. Kavallaris, and D. S. Ziegler, “Challenges and Opportunities to Penetrate the Blood-Brain Barrier for Brain Cancer Therapy,” Theranostics 12, no. 10 (2022): 4734–4752.

[150] S. Wu, C. Tsai, and K. Hynynen, “Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective,” Handbook of Experimental Pharmacology 273 (2022): 351–364.

[151] F. Sousa, A. I. Costa-Pereira, A. Cruz, et al., “Intratumoral VEGF Nanotrapper Reduces Gliobastoma Vascularization and Tumor Cell Mass,” Journal of Controlled Release 339 (2021): 381–390.

[152] E. Lee, E. Lee, E. Kong, et al., “An Agonistic Anti-Tie2 Antibody Suppresses the Normal-to-tumor Vascular Transition in the Glioblastoma Invasion Zone,” Experimental & Molecular Medicine 55, no. 2 (2023): 470–484.

[153] Y. Xie, L. He, R. Lugano, et al., “Key Molecular Alterations in Endothelial Cells in human Glioblastoma Uncovered through Single-cell RNA Sequencing,” JCI Insight 6, no. 15 (2021): e150861.

[154] W. Lv, F. Yang, Z. Ge, et al., “Aberrant Overexpression of Myosin 1b in Glioblastoma Promotes Angiogenesis via VEGF-myc-myosin 1b-Piezo1 Axis,” The Journal of Biological Chemistry 300, no. 11 (2024): 107807.

[155] V. C. Keil, G. H. Gielen, B. Pintea, et al., “DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: a Biopsy Study,” Clinical Neuroradiology 31, no. 4 (2021): 1049–1058.

[156] M. Barbaro, H. A. Fine, and R. S. Magge, “Scientific and Clinical Challenges within Neuro-Oncology,” World Neurosurgery 151 (2021): 402–410.

[157] C. Zhao, X. Zhu, J. Tan, C. Mei, X. Cai, and F. Kong, “Lipid-based Nanoparticles to Address the Limitations of GBM Therapy by Overcoming the Blood-Brain Barrier, Targeting Glioblastoma Stem Cells, and Counteracting the Immunosuppressive Tumor Microenvironment,” Biomedicine & Pharmacotherapy 171 (2024): 116113.

[158] M. C. de Gooijer, E. M. Kemper, L. C. Buil, et al., “ATP-binding Cassette Transporters Restrict Drug Delivery and Efficacy against Brain Tumors Even When Blood-Brain Barrier Integrity Is Lost,” Cell Reports Medicine 2, no. 1 (2021): 100184.

[159] V. Podder, S. Bellur, K. Margolin, et al., “Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: a State-of-the-Art Review,” Current Oncology Reports 26, no. 12 (2024): 1612–1638.

[160] M. F. Munoz Pinto, S. J. Campbell, C. Simoglou Karali, et al., “Selective Blood-Brain Barrier Permeabilization of Brain Metastases by a Type 1 Receptor-selective Tumor Necrosis Factor Mutein,” Neuro-Oncology 24, no. 1 (2022): 52–63.

[161] C. Zhang, X. Zhang, J. Wang, et al., “Lnc00462717 regulates the Permeability of the Blood-Brain Tumor Barrier through Interaction with PTBP1 to Inhibit the miR-186-5p/Occludin Signaling Pathway,” FASEB Journal 34, no. 8 (2020): 9941–9958.

[162] Q. Cai, X. Li, H. Xiong, et al., “Optical Blood-Brain-tumor Barrier Modulation Expands Therapeutic Options for Glioblastoma Treatment,” Nature Communications 14, no. 1 (2023): 4934.

[163] H. Wei, P. S. Upadhyayula, A. N. Pouliopoulos, et al., “Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment,” International Journal of Radiation Oncology, Biology, Physics 110, no. 2 (2021): 539–550.

[164] V. A. Ljubimov, A. Ramesh, S. Davani, M. Danielpour, J. J. Breunig, and K. L. Black, “Neurosurgery at the Crossroads of Immunology and Nanotechnology. New Reality in the COVID-19 Pandemic,” Advanced Drug Delivery Reviews 181 (2022): 114033.

[165] M. Choudhari, S. Hejmady, R. Narayan Saha, et al., “Evolving New-age Strategies to Transport Therapeutics across the Blood-Brain-barrier,” International Journal of Pharmaceutics 599 (2021): 120351.

[166] B. Sethi, V. Kumar, K. Mahato, D. W. Coulter, and R. I. Mahato, “Recent Advances in Drug Delivery and Targeting to the Brain,” Journal of Controlled Release 350 (2022): 668–687.

[167] L. Wang, Y. Shi, J. Jiang, et al., “Micro-Nanocarriers Based Drug Delivery Technology for Blood-Brain Barrier Crossing and Brain Tumor Targeting Therapy,” Small 18, no. 45 (2022): e2203678.

[168] J. Liao, L. Gong, Q. Xu, et al., “Revolutionizing Neurocare: Biomimetic Nanodelivery via Cell Membranes,” Advanced Materials 36, no. 26 (2024): e2402445.

[169] L. Han and C. Jiang, “Evolution of Blood-Brain Barrier in Brain Diseases and Related Systemic Nanoscale Brain-targeting Drug Delivery Strategies,” Acta Pharmaceutica Sinica B 11, no. 8 (2021): 2306–2325.

[170] S. Ding, A. I. Khan, X. Cai, et al., “Overcoming Blood-Brain Barrier Transport: Advances in Nanoparticle-based Drug Delivery Strategies,” Materials Today 37 (2020): 112–125.

[171] A. C. Yang, M. Y. Stevens, M. B. Chen, et al., “Physiological Blood-Brain Transport Is Impaired with Age by a Shift in Transcytosis,” Nature 583, no. 7816 (2020): 425–430.

[172] C. M. Gorick, V. R. Breza, K. M. Nowak, et al., “Applications of Focused Ultrasound-mediated Blood-Brain Barrier Opening,” Advanced Drug Delivery Reviews 191 (2022): 114583.

[173] C. Li, T. Sun, and C. Jiang, “Recent Advances in Nanomedicines for the Treatment of Ischemic Stroke,” Acta Pharmaceutica Sinica B 11, no. 7 (2021): 1767–1788.

[174] L. Zhang, H. Sun, J. Zhao, et al., “Dynamic Nanoassemblies for Imaging and Therapy of Neurological Disorders,” Advanced Drug Delivery Reviews 175 (2021): 113832.

[175] B. Li, G. Chen, H. Zhong, et al., “γ-Glutamyl Transpeptidase-activable Nanoprobe Crosses the Blood-Brain Barrier for Immuno-sonodynamic Therapy of Glioma,” Nature Communications 15, no. 1 (2024): 10418.

[176] Z. Du, Y. Li, X. Jiang, and J. Gao, “Nanoparticles Designed Based on the Blood-Brain Barrier for the Treatment of Cerebral Ischemia-Reperfusion Injury,” Small 21, no. 19 (2025): e2410404.

[177] A. D'Souza, K. M. Dave, R. A. Stetler, and D. S. Manickam, “Targeting the Blood-Brain Barrier for the Delivery of Stroke Therapies,” Advanced Drug Delivery Reviews 171 (2021): 332–351.

[178] D. van Straten, H. Sork, L. van de Schepop, R. Frunt, K. Ezzat, and R. M. Schiffelers, “Biofluid Specific Protein Coronas Affect Lipid Nanoparticle Behavior in Vitro,” Journal of Controlled Release 373 (2024): 481–492.

[179] E. P. Cisneros, B. A. Morse, A. Savk, K. Malik, N. A. Peppas, and O. L. Lanier, “The Role of Patient-specific Variables in Protein Corona Formation and Therapeutic Efficacy in Nanomedicine,” Journal of Nanobiotechnology 22, no. 1 (2024): 714.

[180] J. Rabanel, P. Piec, S. Landri, S. A. Patten, and C. Ramassamy, “Transport of PEGylated-PLA Nanoparticles across a Blood Brain Barrier Model, Entry into Neuronal Cells and in Vivo Brain Bioavailability,” Journal of Controlled Release 328 (2020): 679–695.

[181] N. Mamidi and A. O. Mahmoudsalehi, “Advances in Three-dimensional Hydrogel Networks for Cancer Immunotherapy,” Journal of Materials Chemistry B 13, no. 34 (2025): 10440–10459.

[182] X. Cai, A. Refaat, P. Gan, et al., “Angiopep-2-Functionalized Lipid Cubosomes for Blood-Brain Barrier Crossing and Glioblastoma Treatment,” ACS Applied Materials & Interfaces 16, no. 10 (2024): 12161–12174.

[183] S. Lei, Y. Yang, J. Liu, et al., “Nanodrug Delivery Systems for Regulating Microglial Polarization in Ischemic Stroke Treatment: a Review,” Journal of Tissue Engineering 15 (2024): 20417314241237052.

[184] J. Zhu, Y. Zhang, X. Chen, et al., “Angiopep-2 Modified Lipid-coated Mesoporous Silica Nanoparticles for Glioma Targeting Therapy Overcoming BBB,” Biochemical and Biophysical Research Communications 534 (2021): 902–907.

[185] N. Yin, W. Wang, F. Pei, et al., “A Neutrophil Hijacking Nanoplatform Reprograming NETosis for Targeted Microglia Polarizing Mediated Ischemic Stroke Treatment,” Advanced Science 11, no. 17 (2024): e2305877.

[186] N. Mamidi, F. Franco De Silva, and A. Orash Mahmoudsalehi, “Advanced Disease Therapeutics Using Engineered Living Drug Delivery Systems,” Nanoscale 17, no. 13 (2025): 7673–7696.

[187] S. Zhang, B. Peng, Z. Chen, et al., “Brain-targeting, Acid-responsive Antioxidant Nanoparticles for Stroke Treatment and Drug Delivery,” Bioactive Materials 16 (2022): 57–65.

[188] V. Baldim, F. Bedioui, N. Mignet, I. Margaill, and J. Berret, “The Enzyme-like Catalytic Activity of Cerium Oxide Nanoparticles and Its Dependency on Ce3+ Surface Area Concentration,” Nanoscale 10, no. 15 (2018): 6971–6980.

[189] Y. Zhao, Q. Li, J. Niu, et al., “Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy,” Advanced Materials 36, no. 21 (2024): e2311803.

[190] R. H. Fang, W. Gao, and L. Zhang, “Targeting Drugs to Tumours Using Cell Membrane-coated Nanoparticles,” Nature Reviews Clinical Oncology 20, no. 1 (2023): 33–48.

[191] G. Thom, M. Burrell, A. S. Haqqani, et al., “Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26,” Molecular Pharmaceutics 15, no. 4 (2018): 1420–1431.

[192] M. Sela, M. Poley, P. Mora-Raimundo, et al., “Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease,” Advanced Materials 35, no. 51 (2023): e2304654.

[193] B. T. Topçu, S. Bozdağ Pehlivan, Y. Akdağ, M. Mut, and L. Öner, “Antibody Conjugated Nano-Enabled Drug Delivery Systems against Brain Tumors,” Journal of Pharmaceutical Sciences 113, no. 6 (2024): 1455–1469.

[194] X. Shen, H. Li, B. Zhang, Y. Li, and Z. Zhu, “Targeting Transferrin Receptor 1 for Enhancing Drug Delivery through the Blood-Brain Barrier for Alzheimer's Disease,” International Journal of Molecular Sciences 26, no. 19 (2025): 9793.

[195] Y. Shi, L. Han, X. Zhang, L. Xie, P. Pan, and F. Chen, “Selenium Alleviates Cerebral Ischemia/Reperfusion Injury by Regulating Oxidative Stress, Mitochondrial Fusion and Ferroptosis,” Neurochemical Research 47, no. 10 (2022): 2992–3002.

[196] S. Sabra and M. M. Agwa, “Lactoferrin, a Unique Molecule with Diverse Therapeutical and Nanotechnological Applications,” International Journal of Biological Macromolecules 164 (2020): 1046–1060.

[197] M. M. Agwa and S. Sabra, “Lactoferrin Coated or Conjugated Nanomaterials as an Active Targeting Approach in Nanomedicine,” International Journal of Biological Macromolecules 167 (2021): 1527–1543.

[198] J. Zhang, R. Fang, Y. Li, J. Jin, F. Yang, and J. Chen, “Encapsulation of Au(III) Complex Using Lactoferrin Nanoparticles to Combat Glioma,” Molecular Pharmaceutics 20, no. 7 (2023): 3632–3644.

[199] T. I. Janjua, Y. Cao, A. Ahmed-Cox, et al., “Efficient Delivery of Temozolomide Using Ultrasmall Large-pore Silica Nanoparticles for Glioblastoma,” Journal of Controlled Release 357 (2023): 161–174.

[200] S. Awad, M. Araújo, P. Faria, B. Sarmento, and C. Martins, “Chemical Engineering of Zein with Polyethylene Glycol and Angiopep-2 to Manufacture a Brain-targeted Docetaxel Nanomedicine for Glioblastoma Treatment,” Drug Delivery and Translational Research 14, no. 12 (2024): 3585–3598.

[201] X. Liu, C. Xie, Y. Wang, et al., “Ferritinophagy and Ferroptosis in Cerebral Ischemia Reperfusion Injury,” Neurochemical Research 49, no. 8 (2024): 1965–1979.

[202] S. Parvez, M. Kaushik, M. Ali, et al., “Dodging Blood Brain Barrier with ‘Nano’ warriors: Novel Strategy against Ischemic Stroke,” Theranostics 12, no. 2 (2022): 689–719.

[203] J. Nong, P. M. Glassman, V. V. Shuvaev, et al., “Targeting Lipid Nanoparticles to the Blood-Brain Barrier to Ameliorate Acute Ischemic Stroke,” Molecular Therapy 32, no. 5 (2024): 1344–1358.

[204] L. Tang, Y. Yin, H. Liu, et al., “Blood-Brain Barrier-Penetrating and Lesion-Targeting Nanoplatforms Inspired by the Pathophysiological Features for Synergistic Ischemic Stroke Therapy,” Advanced Materials 36, no. 21 (2024): e2312897.

[205] M. Cuypers, T. Jaspers, J. Clerckx, et al., “Increasing Brain Half-life of Antibodies by Additional Binding to Myelin Oligodendrocyte Glycoprotein, a CNS Specific Protein,” Fluids and Barriers of the CNS 22, no. 1 (2025): 11.

[206] M. Gao, Y. Li, W. Ho, et al., “Targeted mRNA Nanoparticles Ameliorate Blood-Brain Barrier Disruption Postischemic Stroke by Modulating Microglia Polarization,” ACS Nano 18, no. 4 (2024): 3260–3275.

[207] J. Wang, Z. Li, M. Pan, et al., “Ultrasound-mediated Blood-Brain Barrier Opening: an Effective Drug Delivery System for Theranostics of Brain Diseases,” Advanced Drug Delivery Reviews 190 (2022): 114539.

[208] D. McMahon, M. A. O'Reilly, and K. Hynynen, “Therapeutic Agent Delivery across the Blood-Brain Barrier Using Focused Ultrasound,” Annual Review of Biomedical Engineering 23 (2021): 89–113.

[209] S. Schoen, M. S. Kilinc, H. Lee, et al., “Towards Controlled Drug Delivery in Brain Tumors with Microbubble-enhanced Focused Ultrasound,” Advanced Drug Delivery Reviews 180 (2022): 114043.

[210] C. Brighi, E. Salimova, M. de Veer, S. Puttick, and G. Egan, “Reply to Letter from Price et al., re: Translation of Focused Ultrasound for Blood-Brain Barrier Opening in Glioma,” Journal of Controlled Release 366 (2024): 879.

[211] A. R. Rezai, M. Ranjan, P. D'Haese, et al., “Noninvasive Hippocampal Blood-Brain Barrier Opening in Alzheimer's disease with Focused Ultrasound,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 17 (2020): 9180–9182.

[212] C. Gasca-Salas, B. Fernández-Rodríguez, J. A. Pineda-Pardo, et al., “Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson's Disease Dementia,” Nature Communications 12, no. 1 (2021): 779.

[213] E. Memari, D. Khan, R. Alkins, and B. Helfield, “Focused Ultrasound-assisted Delivery of Immunomodulating Agents in Brain Cancer,” Journal of Controlled Release 367 (2024): 283–299.

[214] Y. Shen, M. Hu, W. Li, et al., “Delivery of DNA Octahedra Enhanced by Focused Ultrasound with Microbubbles for Glioma Therapy,” Journal of Controlled Release 350 (2022): 158–174.

[215] B. Li, X. Chen, W. Qiu, et al., “Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy,” Advanced Science 9, no. 17 (2022): e2105451.

[216] B. Joshi and A. Joshi, “Polymeric Magnetic Nanoparticles: a Multitargeting Approach for Brain Tumour Therapy and Imaging,” Drug Delivery and Translational Research 12, no. 7 (2022): 1588–1604.

[217] S. Xu, G. Zhang, J. Zhang, W. Liu, Y. Wang, and X. Fu, “Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles,” International Journal of Nanomedicine 18 (2023): 7803–7823.

[218] T. Nguyen, J. Gao, P. Wang, et al., “In Vivo Wireless Brain Stimulation via Non-invasive and Targeted Delivery of Magnetoelectric Nanoparticles,” Neurotherapeutics 18, no. 3 (2021): 2091–2106.

[219] Z. Zheng, J. Chen, Y. Kang, et al., “Dual-responsive Nanoparticle System for Enhanced Blood-Brain Barrier Crossing and Glioblastoma Penetration,” Biomaterials 327 (2026): 123730.

[220] H. Wu, H. Lu, W. Xiao, et al., “Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors,” Advanced Materials 32, no. 14 (2020): e1903759.

[221] L. Lu, K. Wang, C. Lin, et al., “Constructing Nanocomplexes by Multicomponent Self-assembly for Curing Orthotopic Glioblastoma with Synergistic Chemo-photothermal Therapy,” Biomaterials 279 (2021): 121193.

[222] B. Ganjeifar and S. F. Morshed, “Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances,” Current Topics in Medicinal Chemistry 21, no. 14 (2021): 1202–1223.

[223] W. He, Z. Zhang, and X. Sha, “Nanoparticles-mediated Emerging Approaches for Effective Treatment of Ischemic Stroke,” Biomaterials 277 (2021): 121111.

[224] C. Li, Z. Zhao, Y. Luo, et al., “Macrophage-Disguised Manganese Dioxide Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Modulating Inflammatory Microenvironment in Acute Ischemic Stroke,” Advanced Science 8, no. 20 (2021): e2101526.

[225] Y. Liu, X. Wang, X. Li, et al., “A Co-Doped Fe3O4 Nanozyme Shows Enhanced Reactive Oxygen and Nitrogen Species Scavenging Activity and Ameliorates the Deleterious Effects of Ischemic Stroke,” ACS Applied Materials & Interfaces 13, no. 39 (2021): 46213–46224.

[226] U. Carlander, T. P. Moto, A. A. Desalegn, R. A. Yokel, and G. Johanson, “Physiologically Based Pharmacokinetic Modeling of Nanoceria Systemic Distribution in Rats Suggests Dose- and Route-dependent Biokinetics,” International Journal of Nanomedicine 13 (2018): 2631–2646.

[227] L. Tang, C. Fu, A. Zhang, et al., “Harnessing Nanobiotechnology for Cerebral Ischemic Stroke Management,” Biomaterials Science 11, no. 3 (2023): 791–812.

[228] Z. Shen, M. Xiang, C. Chen, et al., “Glutamate Excitotoxicity: Potential Therapeutic Target for Ischemic Stroke,” Biomedicine & Pharmacotherapy 151 (2022): 113125.

[229] Q. J. Wu and M. Tymianski, “Targeting NMDA Receptors in Stroke: New Hope in Neuroprotection,” Molecular Brain 11, no. 1 (2018): 15.

[230] S. P. Yu, M. Q. Jiang, S. S. Shim, S. Pourkhodadad, and L. Wei, “Extrasynaptic NMDA Receptors in Acute and Chronic Excitotoxicity: Implications for Preventive Treatments of Ischemic Stroke and Late-onset Alzheimer's Disease,” Molecular Neurodegeneration 18, no. 1 (2023): 43.

[231] W. Lv, J. Xu, X. Wang, X. Li, Q. Xu, and H. Xin, “Bioengineered Boronic Ester Modified Dextran Polymer Nanoparticles as Reactive Oxygen Species Responsive Nanocarrier for Ischemic Stroke Treatment,” ACS Nano 12, no. 6 (2018): 5417–5426.

[232] B. Peng, F. S. Mohammed, X. Tang, J. Liu, K. N. Sheth, and J. Zhou, “Nanotechnology Approaches to Drug Delivery for the Treatment of Ischemic Stroke,” Bioactive Materials 43 (2024): 145–161.

[233] Z. Wang, Y. Zhao, Y. Jiang, et al., “Enhanced Anti-ischemic Stroke of ZL006 by T7-conjugated PEGylated Liposomes Drug Delivery System,” Scientific Reports 5 (2015): 12651.

[234] C. Qin, W. Fan, Q. Liu, et al., “Fingolimod Protects against Ischemic White Matter Damage by Modulating Microglia toward M2 Polarization via STAT3 Pathway,” Stroke 48, no. 12 (2017): 3336–3346.

[235] X. Hu, P. Li, Y. Guo, et al., “Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion after Focal Cerebral Ischemia,” Stroke 43, no. 11 (2012): 3063–3070.

[236] A. Correia, A. Monteiro, R. Silva, J. Moreira, J. Sousa Lobo, and A. Silva, “Lipid Nanoparticles Strategies to Modify Pharmacokinetics of central Nervous System Targeting Drugs: Crossing or Circumventing the Blood-Brain Barrier (BBB) to Manage Neurological Disorders,” Advanced Drug Delivery Reviews 189 (2022): 114485.

[237] S. M. Weis and D. A. Cheresh, “Pathophysiological Consequences of VEGF-induced Vascular Permeability,” Nature 437, no. 7058 (2005): 497–504.

[238] S. Fernández-García, A. Sancho-Balsells, S. Longueville, et al., “Astrocytic BDNF and TrkB Regulate Severity and Neuronal Activity in Mouse Models of Temporal Lobe Epilepsy,” Cell Death & Disease 11, no. 6 (2020): 411.

[239] C. D. McLoughlin, S. Nevins, J. B. Stein, M. Khakbiz, and K. Lee, “Overcoming the Blood-Brain Barrier: Multifunctional Nanomaterial-Based Strategies for Targeted Drug Delivery in Neurological Disorders,” Small Science 4, no. 12 (2024): 2400232.

[240] C. Zhong, M. Liu, X. Pan, and H. Zhu, “Tumorigenicity Risk of iPSCs in Vivo: Nip It in the Bud,” Precision Clinical Medicine 5, no. 1 (2022): pbac004.

[241] I. R. de Luzy, K. C. L. Law, N. Moriarty, et al., “Human Stem Cells Harboring a Suicide Gene Improve the Safety and Standardisation of Neural Transplants in Parkinsonian Rats,” Nature Communications 12, no. 1 (2021): 3275.

[242] J. Li and D. J. Mooney, “Designing Hydrogels for Controlled Drug Delivery,” Nature Reviews Materials 1, no. 12 (2016): 16071.

[243] N. Mamidi, F. F. De Silva, A. B. Vacas, et al., “Multifaceted Hydrogel Scaffolds: Bridging the Gap between Biomedical Needs and Environmental Sustainability,” Advanced Healthcare Materials 13, no. 27 (2024): e2401195.

[244] A. Zinger, “Unleashing the Potential of Cell Biomimetic Nanoparticles: Strategies and Challenges in Their Design and Fabrication for Therapeutic Applications,” Journal of Controlled Release 358 (2023): 591–600.

[245] S. Đorđević, M. M. Gonzalez, I. Conejos-Sánchez, et al., “Current Hurdles to the Translation of Nanomedicines from Bench to the Clinic,” Drug Delivery and Translational Research 12, no. 3 (2022): 500–525.

[246] F. Wang, A. Harker, M. Edirisinghe, and M. Parhizkar, “Micro- and Nanomanufacturing for Biomedical Applications and Nanomedicine: a Perspective,” Small Science 3, no. 11 (2023): 2300039.

[247] P. J. Gawne, M. Ferreira, M. Papaluca, J. Grimm, and P. Decuzzi, “New Opportunities and Old Challenges in the Clinical Translation of Nanotheranostics,” Nature Reviews Materials 8, no. 12 (2023): 783–798.

[248] E. Candelario-Jalil and S. Paul, “Impact of Aging and Comorbidities on Ischemic Stroke Outcomes in Preclinical Animal Models: a Translational Perspective,” Experimental Neurology 335 (2021): 113494.

[249] F. Fluri, M. K. Schuhmann, and C. Kleinschnitz, “Animal Models of Ischemic Stroke and Their Application in Clinical Research,” Drug Design, Development and Therapy 9 (2015): 3445–3454.

[250] X. Li, Z. Han, T. Wang, et al., “Cerium Oxide Nanoparticles with Antioxidative Neurorestoration for Ischemic Stroke,” Biomaterials 291 (2022): 121904.

[251] M. Migliavacca, C. Correa-Paz, M. Pérez-Mato, et al., “Thrombolytic Therapy Based on Lyophilized Platelet-derived Nanocarriers for Ischemic Stroke,” Journal of Nanobiotechnology 22, no. 1 (2024): 10.

[252] W. Yu, N. Yin, Y. Yang, et al., “Rescuing Ischemic Stroke by Biomimetic Nanovesicles through Accelerated Thrombolysis and Sequential Ischemia-reperfusion Protection,” Acta Biomaterialia 140 (2022): 625–640.

[253] G. D. Vitaliano, J. K. Kim, M. J. Kaufman, et al., “Clathrin-nanoparticles Deliver BDNF to Hippocampus and Enhance Neurogenesis, Synaptogenesis and Cognition in HIV/neuroAIDS Mouse Model,” Communications Biology 5, no. 1 (2022): 236.

[254] N. Wu, X. Sun, C. Zhou, J. Yan, and C. Cheng, “Neuroblasts Migration under Control of Reactive Astrocyte-derived BDNF: a Promising Therapy in Late Neurogenesis after Traumatic Brain Injury,” Stem Cell Research & Therapy 14, no. 1 (2023): 2.

[255] P. Kumthekar, S. Tang, A. J. Brenner, et al., “ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases,” Clinical Cancer Research 26, no. 12 (2020): 2789–2799.

[256] C. Dmello, A. Brenner, D. Piccioni, et al., “Phase II Trial of Blood-Brain Barrier Permeable Peptide-paclitaxel Conjugate ANG1005 in Patients with Recurrent High-grade Glioma,” Neuro-Oncology Advances 6, no. 1 (2024): vdae186.

[257] P. G. Durham, A. Butnariu, R. Alghorazi, G. Pinton, V. Krishna, and P. A. Dayton, “Current Clinical Investigations of Focused Ultrasound Blood-brain Barrier Disruption: a Review,” Neurotherapeutics 21, no. 3 (2024): e00352.

[258] A. Morais, J. J. Locascio, L. H. Sansing, et al., “Embracing Heterogeneity in the Multicenter Stroke Preclinical Assessment Network (SPAN) Trial,” Stroke 54, no. 2 (2023): 620–631.

[259] P. D. Lyden, M. A. Diniz, F. Bosetti, et al., “A Multi-laboratory Preclinical Trial in Rodents to Assess Treatment Candidates for Acute Ischemic Stroke,” Science Translational Medicine 15, no. 714 (2023): eadg8656.

[260] P. Lyden, A. Buchan, J. Boltze, et al., “Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report from STAIR XI,” Stroke 52, no. 9 (2021): 3063–3071.

[261] D. Reyes, A. N. Simpkins, E. Hitomi, et al., “Estimating Perfusion Deficits in Acute Stroke Patients without Perfusion Imaging,” Stroke 53, no. 11 (2022): 3439–3445.

[262] G. Jones, L. Zeng, and J. Kim, “Application of Allometric Scaling to Nanochelator Pharmacokinetics,” ACS Omega 8, no. 30 (2023): 27256–27263.

[263] L. di Biase, A. Bonura, P. M. Pecoraro, S. P. Carbone, and V. Di Lazzaro, “Unlocking the Potential of Stroke Blood Biomarkers: Early Diagnosis, Ischemic vs. Haemorrhagic Differentiation and Haemorrhagic Transformation Risk: a Comprehensive Review,” International Journal of Molecular Sciences 24, no. 14 (2023): 11545.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.